Login to Your Account

BioMarin Rolls the Dice on $289M Deal for LJPC's Riquent in Lupus

By Trista Morrison

Thursday, January 8, 2009
BioMarin Pharmaceutical Inc. agreed to pay up to $289 million for worldwide, ex-Asia Pacific rights to La Jolla Pharmaceutical Co.'s Riquent, despite the lupus drug's checkered past that includes Phase III failures, lost partners and regulatory setbacks. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription